It's been 30 years since Peter Kufer, M.D., vice president of Bispecific T-cell Engager (BiTE®) technology at Amgen, first presented BiTE science to the research community. Over the last three decades, scientists around the world have worked diligently to advance this ground-breaking technology, and their unwavering dedication persists in striving to help those impacted by difficult-to-treat cancers.
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Disclaimer
Amgen Inc. published this content on
20 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
20 June 2024 13:28:04 UTC.